<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00152022</url>
  </required_header>
  <id_info>
    <org_study_id>SPD465-303</org_study_id>
    <nct_id>NCT00152022</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of SPD465 in Adults With Moderately Symptomatic ADHD.</brief_title>
  <official_title>A Phase III, Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel-Group, Safety and Efficacy Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and effectiveness of SPD465 compared to&#xD;
      placebo (a capsule with no medication in it) in the treatment of ADHD. The study will also&#xD;
      look at how SPD465 affects the participants sleep and how they perceive their quality of&#xD;
      life.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 25, 2005</start_date>
  <completion_date type="Actual">November 4, 2005</completion_date>
  <primary_completion_date type="Actual">November 4, 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary measure of efficacy will be the clinician-administered ADHD-rating scale (ADHD-RS-IV)</measure>
    <time_frame>Baseline (following ADHD medication washout of 7-28 days)</time_frame>
    <description>The ADHD-RS-IV consists of 18 items designed to reflect current symptomatology of ADHD. Each item is scored on a 4-point scale ranging from 0 (no symptoms) to three (severe symptoms), with the total score for the rating scale ranging from 0 to 54.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary measure of efficacy will be the clinician-administered ADHD-rating scale (ADHD-RS-IV)</measure>
    <time_frame>Week 1</time_frame>
    <description>The ADHD-RS-IV consists of 18 items designed to reflect current symptomatology of ADHD. Each item is scored on a 4-point scale ranging from 0 (no symptoms) to three (severe symptoms), with the total score for the rating scale ranging from 0 to 54.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary measure of efficacy will be the clinician-administered ADHD-rating scale (ADHD-RS-IV)</measure>
    <time_frame>Week 2</time_frame>
    <description>The ADHD-RS-IV consists of 18 items designed to reflect current symptomatology of ADHD. Each item is scored on a 4-point scale ranging from 0 (no symptoms) to three (severe symptoms), with the total score for the rating scale ranging from 0 to 54.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary measure of efficacy will be the clinician-administered ADHD-rating scale (ADHD-RS-IV)</measure>
    <time_frame>Week 3</time_frame>
    <description>The ADHD-RS-IV consists of 18 items designed to reflect current symptomatology of ADHD. Each item is scored on a 4-point scale ranging from 0 (no symptoms) to three (severe symptoms), with the total score for the rating scale ranging from 0 to 54.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary measure of efficacy will be the clinician-administered ADHD-rating scale (ADHD-RS-IV)</measure>
    <time_frame>Week 4</time_frame>
    <description>The ADHD-RS-IV consists of 18 items designed to reflect current symptomatology of ADHD. Each item is scored on a 4-point scale ranging from 0 (no symptoms) to three (severe symptoms), with the total score for the rating scale ranging from 0 to 54.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary measure of efficacy will be the clinician-administered ADHD-rating scale (ADHD-RS-IV)</measure>
    <time_frame>Week 5</time_frame>
    <description>The ADHD-RS-IV consists of 18 items designed to reflect current symptomatology of ADHD. Each item is scored on a 4-point scale ranging from 0 (no symptoms) to three (severe symptoms), with the total score for the rating scale ranging from 0 to 54.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary measure of efficacy will be the clinician-administered ADHD-rating scale (ADHD-RS-IV)</measure>
    <time_frame>Week 6</time_frame>
    <description>The ADHD-RS-IV consists of 18 items designed to reflect current symptomatology of ADHD. Each item is scored on a 4-point scale ranging from 0 (no symptoms) to three (severe symptoms), with the total score for the rating scale ranging from 0 to 54.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Improvement scale (CG(-I) - assessed at visits 1 through 6/Early Termination (ET)</measure>
    <time_frame>Weeks 1, 2, 3, 4, 5, &amp; 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brown ADD Scale (BADDS) - completed at Baseline and 6/ET visits</measure>
    <time_frame>Baseline visit and weeks 1, 2, 3, 4, 5, &amp; 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adult ADHD Impact Module (AIM-A)-completed at Baseline and 6/ET visits.</measure>
    <time_frame>Baseline visit and weeks 1, 2, 3, 4, 5, &amp; 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh Sleep Quality Index (PSQI) - taken at every visit from Baseline to study completion.</measure>
    <time_frame>Baseline visit and weeks 1, 2, 3, 4, 5, &amp; 6</time_frame>
  </secondary_outcome>
  <enrollment>412</enrollment>
  <condition>Attention Deficit Disorder With Hyperactivity</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary diagnosis of ADHD&#xD;
&#xD;
          -  Baseline ADHD-RS-IV score &gt;= 32&#xD;
&#xD;
          -  Non-pregnant females of childbearing potential must comply with contraceptive&#xD;
             restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significantly underweight or morbidly obese&#xD;
&#xD;
          -  Comorbid psychiatric diagnosis with significant symptoms such as Axis II disorders or&#xD;
             severe Axis I disorders&#xD;
&#xD;
          -  History of seizure, tic disorder, or a current diagnosis and/or family history of&#xD;
             Tourette's Disorder&#xD;
&#xD;
          -  Females who are pregnant or lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2005</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphetamine</mesh_term>
    <mesh_term>Dextroamphetamine</mesh_term>
    <mesh_term>Adderall</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

